计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Pemafibrate is an highly potent and selective peroxisome proliferator-activated receptor alpha (PPARα) agonist (hPPAR EC50 = 1 nM/α, 1.10 μM/γ, 1,58 μM/δ by cell-based reporter assays using respective transfectants). When administered in vivo Pemafibrate is>100-fold more effective than fenofibrate in lowering triglyceride (TG) innormal rats (1 mg/kg p.o.) and in increasing HDL-cholesterol (HDL-C) in humanapoA-I (h-apoA-I) transgenic mice (3 mg/kg p.o.). Compared to other fibrates, pemafibrate′s distinct Y-shaped structure aids in stronger PPAR-α activation, better lipid binding, greater potency, and adaptability tostructural changes caused by binding of coactivators. Pemafibrate shows anti-inflammatory activities like lowering the levels of interleukin-6, tumor necrosis factor-α, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1 (VCAM-1), macrophage marker F4/80). It also exhibits antiatherogenic effects by lowering the levels of certain factors such as plasma triglycerides(TG), TG-rich lipoproteins, and apolipoprotein C-III (apoC-III), and increases lipoprotein lipase (LPL) activity and high-density lipoprotein (HDL) levels. Pemafibrate promotes fibroblast growth factor 21 and contributes to the reduction of insulin resistance.
Application:
Pemafibrate may be used in research studies tostudy its effects on lipid metabolism, inflammation, and cardiovascular health.
Biochem/physiol Actions:
Orally active, highly potent and selective peroxisome proliferator-activated receptor alpha (PPARα) agonist with >100-fold in vivo efficacy than fenofibrate.
Pemafibrate is an orally active, highly potent and selective peroxisome proliferator-activated receptor alpha (PPARα) agonist (hPPAR EC50 = 1 nM/α, 1.10 μM/γ, 1,58 μM/δ by cell-based reporter assays using respective transfectants). When administered in vivo Pemafibrate is >100-fold more effective than fenofibrate in lowering triglyceride (TG) in normal rats (1 mg/kg p.o.) and in increasing HDL-cholesterol (HDL-C) in human apoA-I (h-apoA-I) transgenic mice (3 mg/kg p.o.).
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 苯及其取代衍生物 |
| 亚类(Subclass) | 苯氧乙酸衍生物 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯氧乙酸衍生物 |
| 其他上位类(Alternative Parents) | 苯并噁唑类 苯氧基化合物 茴香醚 苄胺 甲氧基苯 二烷基芳胺 烷基芳基醚 噁唑类 杂芳族化合物 羧酸 一元羧酸及其衍生物 氮杂环化合物 氧环化合物 羰基化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 芳基醚 - 氨基酸 - 茴香醚 - 芳香族杂多环化合物 - 氮杂环 - 吡唑 - 苯并噁唑 - 苄胺 - 羰基 - 羧酰胺基 - 羧酸衍生物 - 二烷基芳基胺 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 甲氧基苯 - 单羧酸或其衍生物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 氧杂环 - 噁唑 - 苯酚醚 - 苯氧基化合物 - 苯氧乙酸酯 |
| 描述(Description) | 该化合物属于苯氧乙酸衍生物类有机化合物。这类化合物含有苯甲醚结构,其中甲基团与乙酸或其衍生物相连。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 6.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|